Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Magnetic Resonance Imaging Pilot Study of Intravenous Glyburide in Traumatic Brain Injury.

Eisenberg HM, Shenton ME, Pasternak O, Simard JM, Okonkwo DO, Aldrich C, He F, Jain S, Hayman EG.

J Neurotrauma. 2019 Aug 27. doi: 10.1089/neu.2019.6538. [Epub ahead of print]

PMID:
31354055
2.

Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial.

Sheth KN, Elm JJ, Molyneaux BJ, Hinson H, Beslow LA, Sze GK, Ostwaldt AC, Del Zoppo GJ, Simard JM, Jacobson S, Kimberly WT.

Lancet Neurol. 2016 Oct;15(11):1160-9. doi: 10.1016/S1474-4422(16)30196-X. Epub 2016 Aug 23.

PMID:
27567243
3.

Effects of Oral Glibenclamide on Brain Contusion Volume and Functional Outcome of Patients with Moderate and Severe Traumatic Brain Injuries: A Randomized Double-Blind Placebo-Controlled Clinical Trial.

Khalili H, Derakhshan N, Niakan A, Ghaffarpasand F, Salehi M, Eshraghian H, Shakibafard A, Zahabi B.

World Neurosurg. 2017 May;101:130-136. doi: 10.1016/j.wneu.2017.01.103. Epub 2017 Feb 7.

PMID:
28185976
4.

Traumatic hemorrhagic brain injury: impact of location and resorption on cognitive outcome.

Martin RM, Wright MJ, Lutkenhoff ES, Ellingson BM, Van Horn JD, Tubi M, Alger JR, McArthur DL, Vespa PM.

J Neurosurg. 2017 Mar;126(3):796-804. doi: 10.3171/2016.3.JNS151781. Epub 2016 May 27.

5.

Long-Term Outcomes in Patients Aged ≤70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis.

Sheth KN, Petersen NH, Cheung K, Elm JJ, Hinson HE, Molyneaux BJ, Beslow LA, Sze GK, Simard JM, Kimberly WT.

Stroke. 2018 Jun;49(6):1457-1463. doi: 10.1161/STROKEAHA.117.020365. Epub 2018 May 22.

6.

Neuropathology of Mild Traumatic Brain Injury: Correlation to Neurocognitive and Neurobehavioral Findings.

Bigler ED.

In: Kobeissy FH, editor. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Chapter 31.

7.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
8.

Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial.

Kimberly WT, Bevers MB, von Kummer R, Demchuk AM, Romero JM, Elm JJ, Hinson HE, Molyneaux BJ, Simard JM, Sheth KN.

Neurology. 2018 Dec 4;91(23):e2163-e2169. doi: 10.1212/WNL.0000000000006618. Epub 2018 Nov 16.

PMID:
30446594
9.

Glibenclamide reduces secondary brain damage after experimental traumatic brain injury.

Zweckberger K, Hackenberg K, Jung CS, Hertle DN, Kiening KL, Unterberg AW, Sakowitz OW.

Neuroscience. 2014 Jul 11;272:199-206. doi: 10.1016/j.neuroscience.2014.04.040. Epub 2014 Apr 30.

PMID:
24792709
10.

Post-operative expansion of hemorrhagic contusions after unilateral decompressive hemicraniectomy in severe traumatic brain injury.

Flint AC, Manley GT, Gean AD, Hemphill JC 3rd, Rosenthal G.

J Neurotrauma. 2008 May;25(5):503-12. doi: 10.1089/neu.2007.0442.

PMID:
18346002
11.

Glyburide is associated with attenuated vasogenic edema in stroke patients.

Kimberly WT, Battey TW, Pham L, Wu O, Yoo AJ, Furie KL, Singhal AB, Elm JJ, Stern BJ, Sheth KN.

Neurocrit Care. 2014 Apr;20(2):193-201. doi: 10.1007/s12028-013-9917-z.

12.

Glyburide Advantage in Malignant Edema and Stroke (GAMES-RP) Trial: Rationale and Design.

Sheth KN, Elm JJ, Beslow LA, Sze GK, Kimberly WT.

Neurocrit Care. 2016 Feb;24(1):132-9. doi: 10.1007/s12028-015-0189-7.

PMID:
26268138
13.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group.

Diabetes Obes Metab. 2009 Feb;11(2):167-76. doi: 10.1111/j.1463-1326.2008.01016.x.

PMID:
19125778
14.

High angular resolution diffusion-weighted imaging in mild traumatic brain injury.

Mohammadian M, Roine T, Hirvonen J, Kurki T, Ala-Seppälä H, Frantzén J, Katila A, Kyllönen A, Maanpää HR, Posti J, Takala R, Tallus J, Tenovuo O.

Neuroimage Clin. 2016 Nov 17;13:174-180. eCollection 2017.

15.

Utility of diffusion tensor imaging in the acute stage of mild to moderate traumatic brain injury for detecting white matter lesions and predicting long-term cognitive function in adults.

Matsushita M, Hosoda K, Naitoh Y, Yamashita H, Kohmura E.

J Neurosurg. 2011 Jul;115(1):130-9. doi: 10.3171/2011.2.JNS101547. Epub 2011 Mar 18.

PMID:
21417709
16.

MRI evidence that glibenclamide reduces acute lesion expansion in a rat model of spinal cord injury.

Simard JM, Popovich PG, Tsymbalyuk O, Caridi J, Gullapalli RP, Kilbourne MJ, Gerzanich V.

Spinal Cord. 2013 Nov;51(11):823-7. doi: 10.1038/sc.2013.99. Epub 2013 Sep 17.

17.

Traumatic brain contusions: a clinical role for the kinin antagonist CP-0127.

Narotam PK, Rodell TC, Nadvi SS, Bhoola KD, Troha JM, Parbhoosingh R, van Dellen JR.

Acta Neurochir (Wien). 1998;140(8):793-802; discussion 802-3.

PMID:
9810446
18.

Traumatic axonal injury: the prognostic value of lesion load in corpus callosum, brain stem, and thalamus in different magnetic resonance imaging sequences.

Moen KG, Brezova V, Skandsen T, Håberg AK, Folvik M, Vik A.

J Neurotrauma. 2014 Sep 1;31(17):1486-96. doi: 10.1089/neu.2013.3258. Epub 2014 Jul 1.

PMID:
24773587
19.

Diffusivity of normal-appearing tissue in acute traumatic brain injury.

Brandstack N, Kurki T, Hiekkanen H, Tenovuo O.

Clin Neuroradiol. 2011 Jun;21(2):75-82. doi: 10.1007/s00062-011-0058-5. Epub 2011 Mar 11.

PMID:
21394634
20.

Inhibition of SUR1 decreases the vascular permeability of cerebral metastases.

Thompson EM, Pishko GL, Muldoon LL, Neuwelt EA.

Neoplasia. 2013 May;15(5):535-43.

Supplemental Content

Support Center